pharma

Eli Lilly investiert 50 Millionen US-Dollar in Absci für KI-gestützte Haarausfall-Therapien

by

Pharmaceutical giant Eli Lilly and Company has moved to expand its footprint in generative biology by leading a $50 million investment round in Absci Corporation, a company specializing in artificial intelligence-driven drug discovery. The funding, which includes $40 million in equity, aims to accelerate the development of novel protein-based therapeutics, with early applications reportedly targeting … Read more

Western PA Pharmacy Tour Spotlights Curtis and Asti’s South Hills

by

The Pharmacy Podcast Network and YARAL Pharma have launched the “Care in Motion” community tour, a strategic initiative designed to highlight the operational challenges and clinical contributions of independent community pharmacies in Western Pennsylvania. The tour focuses on the evolving role of local pharmacists as primary points of contact in the healthcare system, specifically emphasizing … Read more

Reanimated Brains Unlocked: How Bexorg’s BrainEx Tech Revolutionizes AI, Drug Testing & Neuroscience

by

Dr. Helena Fischer • May 26, 2026 • Berlin, Germany Reanimated Brains: How BrainEx Technology Is Revolutionizing AI and Drug Testing In a breakthrough that blurs the line between science fiction and reality, researchers at Bexorg—a cutting-edge bioengineering firm—have developed BrainEx, a platform capable of reanimating brain tissue to function outside the body. This technology, … Read more

Can Pfizer’s Pipeline Replace Lost COVID Revenue & Patent Cliffs?

by

Berlin – Pharmaceutical giant Pfizer faces a critical juncture as it navigates a post-COVID revenue landscape and patent expirations. The company is actively reshaping its research and development pipeline, with a renewed focus on oncology, obesity, and other therapeutic areas, including heart failure. This strategic shift aims to ensure sustained growth and innovation in the … Read more

Josef Hecken to Step Down Early as Head of German G-BA?

by

Berlin – Josef Hecken, the long-serving non-partisan chair of the German Federal Joint Committee (G-BA), appears likely to step down from his position before the end of his current term in 2030. Citing personal and family reasons, Hecken reportedly informed officials he may not be able to fulfill the entirety of his mandate, according to … Read more